Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study.
Giorgio Walter CanonicaPaola RottoliCaterina BuccaMaria Cristina ZappaGiovanni MichettiBruno MacciocchiCristiano CarusoPierachille SantusMarta BartezaghiLaura Rigoninull nullPublished in: The World Allergy Organization journal (2018)
This study demonstrated that in severe allergic asthma, omalizumab improves patient-reported outcomes such as patients' illness perception and QoL, while confirming improvement of asthma control and exacerbation rate reduction in Italian patients.
Keyphrases
- patient reported outcomes
- chronic obstructive pulmonary disease
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- allergic rhinitis
- lung function
- prognostic factors
- peritoneal dialysis
- early onset
- cystic fibrosis
- air pollution
- intensive care unit
- smoking cessation
- replacement therapy